Unicycive Therapeutics, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing; it does not provide a separate fourth-quarter results breakdown. Financial statements are audited and prepared under U.S. GAAP. The auditor gave an unqualified opinion on the financial statements, but did not attest to internal control effectiveness.
Business context
Unicycive is a development-stage biotechnology company with no product revenue to date. Its two kidney-disease candidates are Renazorb, for hyperphosphatemia in chronic kidney disease, and UNI 494, for acute kidney injury. The company relies on licensed assets and third-party research, clinical, and manufacturing providers.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $6.080 million | $1.015 million |
| General and administrative expense | $2.897 million | $1.005 million |
| Total operating expenses | $8.977 million | $2.020 million |
| Net loss | $10.017 million | $2.264 million |
| Net loss per share, basic and diluted | $0.86 | $0.27 |
| Net cash used in operating activities | $5.767 million | $1.459 million |
Operating expenses rose 344% and net loss increased 342% year over year. R&D increased 499%, including a $2.191 million noncash charge for final anti-dilution shares issued to Spectrum, higher development and preclinical costs, and increased personnel and stock compensation. G&A rose 188%, reflecting higher insurance, staffing, professional services, and stock compensation. Other expenses included $628,000 of interest and a $431,000 noncash loss on conversion of debt; a $19,000 gain on extinguishment of the PPP loan partly offset these costs. No operating margin or gross margin is meaningful because the company had no revenue.
At December 31, 2021, cash was $16.579 million, current assets $18.411 million, total assets $18.744 million, and total liabilities $2.260 million. Current liabilities were $2.105 million, including a $151,000 current operating lease liability; total lease liabilities were $306,000. Convertible notes and the stockholder loan had been eliminated from the year-end balance sheet following IPO conversion and repayment. Operating cash outflow was $5.767 million, investing outflow $29,000, and financing inflow $22.375 million. Management said the cash balance and expected spending supported operations for at least one year after the financial statements were issued, while also stating that substantial additional capital will be needed.
Material changes and significant transactions
- In July 2021, the company completed its IPO, receiving approximately $22.3 million in net proceeds. It issued 5.0 million shares at $5.00 per unit and began trading on Nasdaq under UNCY.
- Convertible notes and accrued interest converted at the IPO; the conversion issued 736,773 common shares and 184,193 warrants. IPO and noteholder warrants outstanding totaled 4,784,193, with a $6.00 exercise price and five-year term.
- Common shares outstanding increased from 8.514 million at year-end 2020 to 14.997 million at year-end 2021. The filing reports additional share dilution from options and warrants.
- The final Spectrum anti-dilution issuance was 438,374 shares in 2021. Spectrum also retains contractual rights to a portion of certain sublicense income.
- The company entered a two-year office lease in December 2021. It reported no pending legal claims or proceedings expected to have a material adverse effect.
Outlook, risks, and unusual matters
- Renazorb: A Phase 1 study in 32 healthy volunteers was completed in 2012; it showed phosphate-binding effects and was reported as well tolerated. After the reporting year, a March 2022 FDA meeting confirmed that a bioequivalence study in healthy volunteers and an agreed toxicology study could support a 505(b)(2) NDA. The company planned the study and targeted an NDA filing by year-end 2022 or early 2023; these were forward-looking goals, not completed outcomes in this 10-K.
- UNI 494: The candidate remained preclinical. The company planned repeat-dose toxicology and other IND-enabling work in 2022 before clinical development. It reported greater nicorandil exposure in preclinical dog testing, but human efficacy and safety for UNI 494 were not established. Nicorandil’s known risks include headaches and rare, potentially serious gastrointestinal ulceration.
- The company expects continuing losses and negative operating cash flow and will need additional financing. Failure to raise capital could delay, reduce, or stop development, or require licensing rights on unfavorable terms. The filing does not provide numerical revenue or earnings guidance.
- Key risks include uncertain clinical and regulatory outcomes, patient enrollment, reliance on CROs and contract manufacturers, competition, intellectual-property and licensing risks, reimbursement and pricing pressures, and potential COVID-19-related disruption.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end due to a material weakness: insufficient accounting personnel and inadequate formal controls, review, and segregation of duties. Management planned remediation by the end of 2022; success was not assured.
- Related-party matters include services from Globavir, whose CEO is also Unicycive’s CEO; the company recorded $148,000 of service-fee expense in 2021 and wrote off a $28,000 prepaid balance. The CEO also had a stockholder loan that was repaid during 2021.
Investor verification priorities
- Confirm subsequent cash burn, financing activity, and the company’s current runway relative to its stated development plans.
- Check whether the Renazorb bioequivalence and toxicology work was completed, whether the FDA agreed with the resulting data, and whether an NDA was filed or accepted.
- Verify UNI 494’s progress through IND-enabling studies and any clinical-trial authorization, including safety considerations related to nicorandil.
- Review dilution from outstanding options and warrants, as well as Spectrum’s sublicense-income rights and any remaining license or milestone obligations.
- Check whether the disclosed material weakness was remediated and whether later filings report effective controls.
- Reconcile the filing’s differing estimates of U.S. ESRD patients with hyperphosphatemia, which are stated as approximately 400,000 in one section and approximately 500,000 elsewhere; market and patient estimates are not company revenue or validated commercial demand.